Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
OHIP does cover medical Botox for specific indications (chronic migraine, cervical dystonia, hyperhidrosis with documented failure of topical therapy) when administered by an authorized physician and pre-approved by the program
Epub 2023/03/01
10mg vial2mg/mL 5mL 1
Gastrointestinal Health: Research indicates BPC-157 could improve digestive disorders, such as healing ulcers and mitigating NSAID-induced damage
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
K., Adams, R., Wang, Z., Klaunig, J
Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies
US$ 23.22
US$ 26.28
US$ 20.51
